特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
358687

成長ホルモン分泌促進物質受容体(タイプ1):パイプライン分析

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 85 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.56円
成長ホルモン分泌促進物質受容体(タイプ1):パイプライン分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 85 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

成長ホルモン分泌促進物質受容体(GHSR)は、グレリン受容体としても知られているGタンパク質共役受容体であり、グレリンを結合します。グレリンは、下垂体に成長ホルモンを分泌させるレセプターと結合することによって周辺器官から分泌される食欲調整因子です。グレリンを成長ホルモン分泌促進物質受容体(GHSR1a)に結びつけることで活性化する経路は、様々な細胞組織の中でマイトジェン(分裂促進因子)活性化プロテイン、Akt、一酸化窒素シンターゼおよびAMPKカスケードの活性化の管理をしています。グレリン受容体用逆作用薬は、特に肥満の治療において注目されています。

当レポートでは、成長ホルモン分泌促進物質受容体(タイプ1)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報、最近のニュースや発表などを提供しています。

イントロダクション

  • 調査範囲

概要

治療薬の開発

  • 開発段階別
  • 治療領域別
  • 症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/研究機関で開発中の製品

治療薬の評価

  • 単剤併/用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AstraZeneca Plc
  • Aeterna Zentaris Inc.
  • Asubio Pharma Co., Ltd.
  • Asubio Pharma Co., Ltd.
  • Alize Pharma SAS
  • Helsinn Healthcare S.A.
  • Pfizer Inc.
  • RaQualia Pharma Inc.
  • Rhythm Pharmaceuticals, Inc.

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Aeterna Zentaris Inc, H1 2020
  • Pipeline by Allergan Plc, H1 2020
  • Pipeline by AstraZeneca Plc, H1 2020
  • Pipeline by Extend Biosciences Inc, H1 2020
  • Pipeline by Helsinn Group, H1 2020
  • Pipeline by Lumos Pharma Inc, H1 2020
  • Pipeline by Millendo Therapeutics Inc, H1 2020
  • Pipeline by Oxeia Biopharmaceuticals Inc, H1 2020
  • Pipeline by Pfizer Inc, H1 2020
  • Pipeline by RaQualia Pharma Inc, H1 2020
  • Pipeline by TheraSource LLC, H1 2020
  • Pipeline by Zeria Pharmaceutical Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC2365TDB

Summary:

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3, 9 and 1 respectively.

Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Toxicology, Cardiovascular, Genetic Disorders, Hormonal Disorders, Metabolic Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders and Women's Health which include indications Cancer Anorexia-Cachexia Syndrome, Growth Hormone Deficiency, Obesity, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Born Small For Gestational Age (SGA), Cachexia, Chemotherapy Effects, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Gastroparesis, Endocrine Gland Disorders, Fatigue, Ischemia, Prader-Willi Syndrome (PWS), Sepsis, Traumatic Brain Injury and Turner Syndrome.

The latest report Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
  • Aeterna Zentaris Inc
  • Allergan Plc
  • AstraZeneca Plc
  • Extend Biosciences Inc
  • Helsinn Group
  • Lumos Pharma Inc
  • Millendo Therapeutics Inc
  • Oxeia Biopharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • TheraSource LLC
  • Zeria Pharmaceutical Co Ltd
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
  • anamorelin hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZ-12861903 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXT-405 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXT-418 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ibutamoren mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • livoletide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • macimorelin acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OXE-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-05190457 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • relamorelin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RQ-00433412 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GHSR for Cachexia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Z-505 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 07, 2020: Aeterna Zentaris announces EMA decision to accept a modification to an agreed pediatric investigation plan for macimorelin
  • Apr 06, 2020: Millendo Therapeutics announces topline results for pivotal phase 2b study of Livoletide in patients with Prader-Willi Syndrome (PWS)
  • Apr 06, 2020: Aeterna Zentaris announces positive results in dose-finding pediatric study of macimorelin
  • Mar 12, 2020: Aeterna Zentaris announces settlement of previously disclosed class-action lawsuit
  • Feb 12, 2020: Aeterna Zentaris to present at Noble Capital Markets' 16th Annual Investor Conference
  • Jan 28, 2020: Aeterna Zentaris announces completion of patient recruitment in dose-finding pediatric study of Macimorelin
  • Dec 18, 2019: Aeterna Zentaris announces publication of GHD Management Guidelines
  • Nov 14, 2019: Millendo closes enrolment for first part of livoletide's ZEPHYR trial
  • Nov 07, 2019: Millendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019
  • Sep 26, 2019: Millendo Therapeutics to present at Prader-Willi Syndrome Conferences
  • Aug 01, 2019: UAB and Children's of Alabama to investigate new treatment for patients with Prader-Willi syndrome
  • May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
  • May 08, 2019: Millendo Therapeutics announces 21st European Congress of Endocrinology 2019 presentations on Livoletide for Prader-Willi syndrome
  • Mar 19, 2019: Millendo Therapeutics initiates pivotal Phase 2b/3 clinical study of livoletide for the treatment of Prader-Willi Syndrome
  • Mar 14, 2019: Millendo Therapeutics announces ENDO 2019 presentation on livoletide for Prader-Willi Syndrome
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.